Cart
sales@molnova.com
Atezolizumab
CAS No. 1380723-44-3
Atezolizumab ( —— )
Catalog No. M22134 CAS No. 1380723-44-3
Atezolizumab anti-PD-L1) is a fully humanized IgG1 monoclonal antibody that blocks the interaction of PD-L1 with both PD-1 and B7.1 but not the interaction of PD-L2 with PD-1.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 489 | In Stock |
|
| 10MG | 717 | In Stock |
|
| 25MG | 1071 | In Stock |
|
| 50MG | 1467 | In Stock |
|
| 100MG | 1962 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameAtezolizumab
-
NoteResearch use only, not for human use.
-
Brief DescriptionAtezolizumab anti-PD-L1) is a fully humanized IgG1 monoclonal antibody that blocks the interaction of PD-L1 with both PD-1 and B7.1 but not the interaction of PD-L2 with PD-1.
-
DescriptionAtezolizumab anti-PD-L1) is a fully humanized IgG1 monoclonal antibody that blocks the interaction of PD-L1 with both PD-1 and B7.1 but not the interaction of PD-L2 with PD-1.
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOther Targets
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1380723-44-3
-
Formula Weight145 kDa
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Inman BA, et al. Atezolizumab: A PD-L1-Blocking Antibody for Bladder Cancer. Clin Cancer Res. 2017 Apr 15;23(8):1886-1890.
molnova catalog
related products
-
Malotilate
Malotilate, diisopropyl 1,3-dithiol-2-ylidenemalonate, is a drug used for the treatment of liver cirrhosis.
-
1H-Indole-3-ethanami...
1H-Indole-3-ethanamine, 5-bromo-N,N-dimethyl-, hydrochloride is a marine derived natural products found in Smenospongia echina.
-
MBX-4132
MBX-4132, inhibit trans translation by binding to the bacterial ribosome,is a member of a chemical class called oxadiazoles.
